相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease
M. Delvincourt et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe: The ECCO-EpiCom Cohort
Johan Burisch et al.
INFLAMMATORY BOWEL DISEASES (2014)
Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with Inflammatory Bowel Disease - An ECCO-EpiCom study
J. Burisch et al.
JOURNAL OF CROHNS & COLITIS (2014)
Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status
Toshihiro Inokuchi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
A Random Urine Test Can Identify Patients at Risk of Mesalamine Non-Adherence: A Prospective Study
Anne E. Gifford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Understanding Patients' Adherence-Related Beliefs about Medicines Prescribed for Long-Term Conditions: A Meta-Analytic Review of the Necessity-Concerns Framework
Rob Horne et al.
PLOS ONE (2013)
The prevalence and risk factors of cytomegalovirus infection in inflammatory bowel disease in Wuhan, Central China
Fengming Yi et al.
VIROLOGY JOURNAL (2013)
The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients
D. Solomon et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
Simon P. L. Travis et al.
GUT (2012)
Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): Methodology and initial results
Millie D. Long et al.
INFLAMMATORY BOWEL DISEASES (2012)
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease
Geert D'Haens et al.
INFLAMMATORY BOWEL DISEASES (2012)
Strategies in maintenance for patients receiving long-term therapy (SIMPLE): A study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis
Sunanda Kane et al.
INFLAMMATORY BOWEL DISEASES (2012)
Monitoring inflammatory bowel disease activity: Clinical activity is judged to be more relevant than endoscopic severity or biomarkers
Alain M. Schoepfer et al.
JOURNAL OF CROHNS & COLITIS (2012)
Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naive patients with ulcerative colitis
M. De Vos et al.
JOURNAL OF CROHNS & COLITIS (2012)
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing - ASCEND I and II combined analysis
G. R. Lichtenstein et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Nicholas J. Talley et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database
Sunanda V. Kane et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Impact of a Tailored Patient Preference Intervention in Adherence to 5-Aminosalicylic Acid Medication in Ulcerative Colitis: Results from an Exploratory Randomized Controlled Trial
Tetyana Moshkovska et al.
INFLAMMATORY BOWEL DISEASES (2011)
Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine
Pia Munkholm et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2010)
E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach
Margarita Elkjaer et al.
GUT (2010)
Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease
Peter Laszlo Lakatos et al.
JOURNAL OF CROHNS & COLITIS (2010)
High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patients' organization: a patient empowerment study
J. E. Baars et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares
P. D. R. Higgins et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis
Axel U. Dignass et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Effect of Extended MMX Mesalamine Therapy for Acute, Mild-to-Moderate Ulcerative Colitis
Michael A. Kamm et al.
INFLAMMATORY BOWEL DISEASES (2009)
Ulcerative Colitis: Correlation of the Rachmilewitz Endoscopic Activity Index with Fecal Calprotectin, Clinical Activity, C-reactive Protein, and Blood Leukocytes
Alain M. Schoepfer et al.
INFLAMMATORY BOWEL DISEASES (2009)
MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations
G. R. Lichtenstein et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
M. A. Kamm et al.
GUT (2008)
European evidence-based Consensus on the management of ulcerative colitis: Current management
S. P. L. Travis et al.
JOURNAL OF CROHNS & COLITIS (2008)
Mesalamine with MMX™ technology for the treatment of ulcerative colitis
Stefan Schreiber et al.
Expert Review of Gastroenterology & Hepatology (2008)
Nonadherence in inflammatory bowel disease:: Results of factor analysis
Petr Cerveny et al.
INFLAMMATORY BOWEL DISEASES (2007)
Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort
Kathrine Frey Froslie et al.
GASTROENTEROLOGY (2007)
Predictors of medication adherence in inflammatory bowel disease
Jason P. Ediger et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2007)
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
Gary R. Lichtenstein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis
Michael A. Kamm et al.
GASTROENTEROLOGY (2007)
Systematic review: adherence issues in the treatment of ulcerative colitis
SV Kane
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Symptom perception and adherence to asthma controller medications
Ruth Ohm et al.
JOURNAL OF NURSING SCHOLARSHIP (2006)
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study
P Marteau et al.
GUT (2005)
Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis
PDR Higgins et al.
GUT (2005)
Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease
MJ Shale et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Hepatitis A virus VP3 may activate serum response element associated transcription
T Kanda et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2003)
Defining relapse of ulcerative colitis using a symptom-based activity index
SL Jowett et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2003)
分享论文
